Cardioplegia Solution Adverse Reaction Clinical Trial
Official title:
Outcome of Esmolol Potassium Cardioplegia Compared to Potassium Cardioplegia in Patients With Solitary Valvular Disease; Randomized Controlled Study
Perioperative myocardial injury remains one of the most serious complications of cardiac
surgery.
Numerous factors have been implicated during the pathogenesis process, including the
technique of cardiac surgery, induction of cardioplegia and period of cardiac arrest.
Lactic acid is the normal endpoint of the anaerobic breakdown of glucose in the tissues. The
lactate exits the cells and is transported to the liver, thus it's considered to be an
indicator of ischemia as it is produced by most tissues in the human body, with the highest
level of production found in muscle.
In any cardiac valve replacement surgery, patient must undergo cardiac bypass and arrest in
diastole by using hyperkalemic cardioplegia solution; meanwhile the metabolism of myocardial
cells is purely anaerobic.
Esmolol an ultra-short beta blocker is supposed to decrease the anaerobic insult to the
myocardial cells.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05603429 -
Investigation of Myocardial Protection Level With Specific Cardioplegia Methods in Cardiac Surgery
|
||
| Completed |
NCT05221294 -
Modified Del Nido Versus Custodiol Cardioplegia For Myocardial Protection In Cardiac Surgery.
|
N/A | |
| Completed |
NCT04309994 -
Combined Use of a Novel Cardioplegic Formula With MPS® Versus Cardioplexol ® in Urgent Isolated CABG Using MiECC in Patients With Recent Acute Myocardial Infarction
|
||
| Completed |
NCT04203680 -
Histidine-Tryptophan-Ketoglutarate Solution Versus Blood Cardioplegia in CABG
|
Early Phase 1 |